Decreasing undesirable absorbed radiation to the intestine after administration of radium-223 dichloride for treatment of bone metastases

[(223)Ra]RaCl(2) is the first alpha-particle emitting radiopharmaceutical to be used for castration-resistant prostate cancer patients with bone metastases because of its excellent therapeutic effects. [(223)Ra]RaCl(2) is excreted via the intestine into feces, and some is absorbed from the intestine...

Descripción completa

Detalles Bibliográficos
Autores principales: Ogawa, Kazuma, Higashi, Takuma, Mishiro, Kenji, Wakabayashi, Hiroshi, Shiba, Kazuhiro, Odani, Akira, Kinuya, Seigo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368038/
https://www.ncbi.nlm.nih.gov/pubmed/32681007
http://dx.doi.org/10.1038/s41598-020-68846-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7368038/
https://www.ncbi.nlm.nih.gov/pubmed/32681007
http://dx.doi.org/10.1038/s41598-020-68846-x

Ejemplares similares